Peptides for Gut Health and Inflammation: BPC-157, KPV, LL-37, Thymosin Alpha-1 - Evidence Review

Key takeaways

• No peptide sold online for inflammation has a human trial in any gut disease. BPC-157 and KPV have rodent colitis and fistula data, thymosin alpha-1 has human data only for immune conditions such as sepsis, and LL-37 has human data only as a topical wound treatment, where its largest trial missed its main goal.
• The peptides that do work in the gut are prescription drugs that went through randomized trials: linaclotide for constipation-predominant IBS and teduglutide for short bowel syndrome. Larazotide, a peptide designed to tighten the 'leaky' gut lining, passed one phase 2 trial at its lowest dose and then had its phase 3 stopped; even a well-run peptide program can fail.
• Our ranking of the marketed peptides for gut health and inflammation: BPC-157 first and KPV second, both grade D and close to tied; thymosin alpha-1 third, because its human data are not about the gut; LL-37 fourth, because what is known about it in people points in both directions on inflammation.
• Two food comparisons: glutamine, an amino acid, has one positive randomized trial in a narrow group of people with post-infectious IBS; collagen has no controlled gut trial.
• None of the four peptides can be compounded by a US pharmacy as of October 2026. If you have a diagnosed inflammatory condition, guideline treatment is the place to start, and no peptide here is a substitute for it.

Search 'peptides for inflammation' and you get BPC-157, KPV, LL-37 and thymosin alpha-1, often sold as capsules for the gut or as injectable stacks. This guide ranks them by the human evidence PubMed contains, then holds them against the treatments with real trials for inflammatory bowel disease, irritable bowel syndrome and inflammation elsewhere in the body. The short answer: all four are research chemicals with no human gut trial and no legal compounded form. Our BPC-157 profile, KPV profile, KPV vs BPC-157 comparison and thymosin alpha-1 profile carry the full evidence tables; BPC-157 for gut health sorts the rodent gut data by condition, and oral BPC-157 vs injection deals with capsules.

How we ranked

Four criteria, in order: human evidence for a gut or inflammatory condition, graded A to D under our editorial policy; legal status in the United States as of October 2026; safety; and cost. We searched PubMed and ClinicalTrials.gov for each compound on October 10, 2026 and graded each by its best human study for the use it is marketed for. Popularity, testimonials and seller claims did not count. Because the conditions people buy these products for (colitis, Crohn's disease, IBS, 'leaky gut', chronic inflammation) range from nuisance to dangerous, the treatments with trials come first, and each peptide faces one question: is there evidence to use it instead of, or alongside, them?

The ranking

Grades describe the evidence for gut and inflammatory conditions only. The gap between the benchmark rows and rank 1 is the main finding of this guide.

The benchmark: what works

Ulcerative colitis and Crohn's disease. The 2025 American College of Gastroenterology guideline grades every ulcerative colitis option by disease severity and by the quality of the trials behind it: mesalamine for mild-to-moderate disease, corticosteroids to induce remission in flares, thiopurines, biologics against TNF, integrins and the IL-12/23 and IL-23 pathways, JAK inhibitors and S1P modulators (Rubin 2025). Several of the most effective are antibodies, large proteins made under FDA-inspected manufacturing, which is the opposite of a research vial. They suppress parts of the immune system and come with infection screening and monitoring.

Irritable bowel syndrome. IBS is not an inflammatory disease in the IBD sense, but it is the most common reason people buy 'gut' peptides. The first ACG guideline on IBS recommends or suggests a positive diagnosis rather than endless exclusion, celiac serology and fecal calprotectin in people with diarrhea to rule out other disease, a limited trial of a low-FODMAP diet, chloride channel activators and guanylate cyclase activators for IBS with constipation, rifaximin for IBS with diarrhea, and gut-directed psychotherapy (Lacy 2021). The first guanylate cyclase activator, linaclotide, is itself a 14-amino-acid peptide taken by mouth; it acts on the gut lining and is barely absorbed. It is the clearest example of an oral gut peptide that earned its claims in randomized trials.

Short bowel syndrome. Teduglutide is a GLP-2 analog, a peptide that thickens the intestinal lining. In a 24-week trial, 86 adults with short bowel syndrome dependent on intravenous nutrition received 0.05 mg/kg a day under the skin or placebo; 63 percent of the teduglutide group cut their intravenous support by more than 20 percent, against 30 percent on placebo, and weekly volume fell by 4.4 versus 2.3 liters (Jeppesen 2012). It is FDA-approved for that use.

Celiac disease and the 'leaky gut' idea. Larazotide is the cautionary benchmark. An eight-amino-acid peptide designed to tighten the junctions between gut cells, it was tested in 342 adults with celiac disease who still had symptoms on a gluten-free diet: the 0.5 mg dose three times daily reduced symptoms more than placebo, while the 1 and 2 mg doses did no better than placebo (Leffler 2015). The phase 3 trial enrolled 307 people and was terminated by its sponsor in 2022, which said an interim analysis showed it would need far more patients to separate from placebo; no results have been posted (NCT03569007). It is not approved. A barrier-tightening peptide with a proper trial program still did not make it, which is worth remembering when a vial promises to 'seal' a leaky gut.

Systemic inflammation. 'Chronic inflammation' is not a diagnosis; a raised CRP points to a cause, such as obesity, infection, autoimmune disease or atherosclerosis, and treating that cause is the evidence-based move. Where inflammation itself has been treated as a target and tested on hard outcomes, the winner is an old tablet. In the LoDoCo2 trial, 5,522 people with stable coronary disease took colchicine 0.5 mg daily or placebo for a median of 28.6 months; colchicine cut the composite of cardiovascular death, heart attack, ischemic stroke and ischemia-driven revascularization by 31 percent (hazard ratio 0.69), and it is now FDA-approved for that purpose. Its label lists dangerous interactions with strong CYP3A4 and P-glycoprotein inhibitors and contraindications in kidney failure and severe liver disease (Lodoco label). That is what an anti-inflammatory claim looks like with evidence behind it.

1. BPC-157: the most rodent gut data, no human gut trial

BPC-157 is a synthetic 15-amino-acid fragment of a protein from human gastric juice. In rats it has protected the stomach lining from alcohol and anti-inflammatory drugs and healed chemically induced colitis, bowel anastomoses and fistulas. A representative study created a colon-to-skin fistula in rats and gave BPC-157 at 10 mcg/kg or 10 ng/kg, in drinking water or by daily injection, for up to 28 days: both routes and both doses closed the fistulas faster than controls, sulfasalazine was only moderately effective and a corticosteroid made healing worse (Klicek 2008). The paper's title describes the peptide as 'in clinical trials' for inflammatory bowel disease under the code PL 14736; no result of that program has ever been published.

The human record, as counted by a 2026 drug-development review, is fewer than 30 people in three uncontrolled pilot studies, in knee pain, interstitial cystitis and intravenous safety; none involved the gut (Mateescu 2026). Almost all of the animal work comes from the Zagreb laboratory that discovered the peptide. BPC-157 was nominated to FDA's compounding list for ulcerative colitis, FDA's reviewers opposed it for lack of human data, and the advisory committee voted 8-6-1 in favor on July 23, 2026; no rule has followed, so no US pharmacy may compound it (legal tracker).

Grade: D. Legal status: not approved, not compoundable. Cost: no legal product exists, so any price is for a research vial. Who it is for: nobody outside a clinical trial. It ranks first among the marketed peptides only because it has the largest gut-specific animal literature and formal animal toxicology; BPC-157 for gut health breaks those data down by condition.

2. KPV: mouse colitis and a clear mechanism, no human study

KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone, a fragment that keeps the hormone's anti-inflammatory signal and loses its tanning effect. It enters gut and immune cells through PepT1, a peptide transporter that the inflamed colon switches on, and inside the cell it blocks NF-kappa-B at nanomolar concentrations. In mice given dextran sulfate sodium, which strips the colon lining, or a second irritant, TNBS, KPV added to the drinking water reduced colitis and inflammatory cytokine expression (Dalmasso 2008). Two other laboratories have published supportive mouse colitis work, covered in the KPV profile.

There is no human study of KPV of any kind, published or registered. A related but different tripeptide, KdPT, reached a small phase 2a trial in ulcerative colitis; it is not what is in a KPV capsule. KPV got the same 8-6-1 committee vote as BPC-157 in July 2026, for wound healing and inflammatory conditions, and the same absence of a rule.

Grade: D. Legal status: not approved, not compoundable. Who it is for: nobody outside a trial. It ranks just behind BPC-157 on safety information, not on efficacy: KPV has independent replication and a better-understood mechanism, but no human exposure data and no formal toxicology. The comparison explains why the 'BPC-157 plus KPV' capsules double the unknowns.

3. Thymosin alpha-1: an immune drug abroad, not a gut drug

Thymosin alpha-1 is a 28-amino-acid peptide from the thymus that modulates T-cell responses. It is sold as a prescription drug in a number of countries outside the US, mainly for hepatitis B, and it is marketed in the US for 'immune support' and 'chronic inflammation'. Its best test against inflammation is sepsis, the body-wide inflammatory response to infection. In a double-blind trial at 22 Chinese hospitals, 1,106 adults with sepsis received subcutaneous thymosin alpha-1 or placebo every 12 hours for seven days; 28-day mortality was 23.4 percent versus 24.1 percent (hazard ratio 0.99), and no secondary or safety outcome differed (Wu 2025). We found no trial of thymosin alpha-1 in inflammatory bowel disease, IBS or any other gut condition.

Thymosin alpha-1 was placed in FDA's Category 2 in 2023 and reviewed by the advisory committee in December 2024, where FDA's reviewers proposed not to add it to the compounding list; it is not compoundable (legal tracker). The thymosin alpha-1 profile covers its hepatitis and vaccine data.

Grade: D for the gut. Legal status: not FDA-approved, not compoundable. Who it is for: not for gut health; its human data are about infection and immunity.

4. LL-37: an antimicrobial peptide that cuts both ways

LL-37 is the only human cathelicidin, a 37-amino-acid antimicrobial peptide made by white cells and by the skin and gut lining. Its human drug data are topical. After a small first trial looked encouraging, a phase 2b trial randomized 148 people with hard-to-heal venous leg ulcers (median duration 20 months) to LL-37 solution at 0.5 or 1.6 mg/mL or placebo, on top of compression; healing did not improve in the study population as a whole, a benefit appeared only in a post hoc subgroup with large wounds, and the drug was well tolerated. Three authors worked for the developer (Mahlapuu 2021).

The gut data are in mice and involve the mouse version of the peptide. Cathelicidin expression rises in inflamed colon tissue, and mice bred without it develop worse chemically induced colitis (Koon 2011). That suggests the body's own cathelicidin matters; it does not show that injecting synthetic LL-37 helps a human colon, and we found no human gut trial. The complication for anyone buying it 'for inflammation' is that LL-37 can drive inflammation too: in psoriasis, it binds the body's own DNA and turns it into a trigger for interferon production by dendritic cells, a pathway the authors proposed as a driver of the disease (Lande 2007).

LL-37 came off FDA's Category 2 list on April 15, 2026; the advisory committee is due to review it by February 2027, and until FDA lists it no pharmacy may compound it, whatever some clinic summaries say (legal tracker).

Grade: D for the gut; the best human trial, in leg ulcers, was negative on its main endpoint. Legal status: not approved, not compoundable. Who it is for: nobody for gut or general inflammation.

Food and supplement comparisons: glutamine and collagen

Glutamine is an amino acid, not a peptide, and the gut lining uses it as fuel. One randomized trial makes it worth a conversation for a specific group: 106 adults who developed diarrhea-predominant IBS after a gut infection, and who had measurably increased intestinal permeability, took glutamine 5 g three times a day or placebo for eight weeks. A drop of at least 50 points on the IBS severity score occurred in 79.6 percent on glutamine versus 5.8 percent on placebo, and permeability normalized (Zhou 2019). It was a single-center trial with an unusually low placebo response for IBS, so it needs replication, and it says nothing about IBD or IBS in general.

Collagen peptides are a food protein broken into fragments. We found no placebo-controlled trial of collagen for IBS, IBD or 'leaky gut'. The human study usually cited is open-label and single-arm: of 40 women recruited to take 20 g a day for eight weeks, 14 finished, and 13 of them reported fewer digestive symptoms (Abrahams 2022). That is a feasibility study, not evidence of effect. Collagen is a reasonable protein source; it is not a treatment.

What we excluded and why

• Blends (BPC-157 plus KPV capsules, the KLOW and GLOW injectables): no study of any combination exists, and blends make any reaction impossible to attribute. Our GLOW and KLOW page takes them apart.
• TB-500 and GHK-Cu: marketed for healing and skin, with no gut-inflammation evidence; see the TB-500 profile.
• Larazotide: it appears above as a benchmark, but it is not available outside trials.
• Biologics and other approved drugs: they belong to your gastroenterologist, not to a ranking of products you can buy.

How to get real care

Start with a diagnosis. Bloody diarrhea, weight loss, night-time symptoms, anemia, a family history of IBD or colon cancer, or new symptoms after 50 call for a clinician soon, not a supplement; a stool calprotectin test and celiac serology are cheap first steps that the IBS guideline itself suggests (Lacy 2021). Once you have a diagnosis, ask what the guideline-graded options are for your severity, and ask about anything you are tempted to add. If a clinic offers BPC-157, KPV, LL-37 or thymosin alpha-1, ask the tracker's question: which pharmacy, in which state, on what legal basis? In October 2026 there is no good answer for any of the four, and capsules sold as 'supplements' are unapproved drugs in a different package. Never stop or replace prescribed therapy for a research peptide.

Bottom line

The phrase 'peptides for inflammation' covers two very different things. One is a set of approved drugs, some of them peptides, that passed randomized trials for specific gut conditions: linaclotide for IBS with constipation, teduglutide for short bowel syndrome, and the biologic proteins that put many IBD patients into remission. The other is a set of research chemicals, BPC-157, KPV, LL-37 and thymosin alpha-1, with rodent gut data, human data that are not about the gut, or both, and no legal compounded form in the United States. If your gut is inflamed, the first group is where the evidence is. The second group may one day earn a trial; none has one today.

Frequently asked questions

+−What peptides are good for inflammation?

The peptides with strong human evidence against gut inflammation and its consequences are prescription drugs: the antibody biologics a gastroenterologist uses for ulcerative colitis and Crohn's disease (which are large proteins, not the small peptides sold online), linaclotide for constipation-predominant IBS, and teduglutide for short bowel syndrome. The peptides marketed for inflammation online, BPC-157, KPV, LL-37 and thymosin alpha-1, have no human trial in any gut disease, and none can be compounded by a US pharmacy as of October 2026.

+−Is BPC-157 good for inflammation?

In rats it reduced inflammation and sped healing in many injury models, including chemically induced colitis and surgical fistulas, nearly all from one laboratory in Zagreb. In people there is no controlled trial of BPC-157 for any inflammatory condition; the published human record is three small uncontrolled pilots in knee pain, interstitial cystitis and intravenous safety, about 30 people in total. FDA's reviewers found no adequate human data when it was nominated for ulcerative colitis in 2026.

+−Is BPC-157 good for gut health?

It protected the stomach and bowel lining in rodents and healed experimental colitis and fistulas, but it has never been tested in a person with a gut condition. A Croatian company's inflammatory bowel disease program from the 2000s never published results. If you have ulcers, colitis, Crohn's disease or IBS, the treatments with human trials are the ones a clinician prescribes; our article on BPC-157 for gut health goes through the rodent data condition by condition.

+−What is the LL-37 peptide used for?

LL-37 is the only human cathelicidin, an antimicrobial peptide made by white cells and the skin and gut lining. As a drug it has been tested mainly as a topical solution for chronic leg ulcers; the largest trial, in 148 patients, found no overall improvement in healing over placebo. It has no human trial for gut disease, and the same peptide helps trigger the immune reaction behind psoriasis, so 'anti-inflammatory' is not an accurate label. It cannot be compounded in the US as of October 2026.

+−What is thymosin alpha-1 good for?

Thymosin alpha-1 is a thymus peptide that modulates immune responses and is sold as a prescription drug in a number of countries outside the US, mainly for hepatitis B. In the largest randomized trial, 1,106 adults with sepsis, it did not reduce 28-day mortality. It has no trial in any gut disease, it is not FDA-approved, and US pharmacies may not compound it.

+−Are peptide supplements for inflammation legal?

A peptide sold to treat a disease is a drug, not a dietary supplement, whatever the label says. BPC-157 and KPV were recommended for the compounding list by an FDA committee in July 2026 but no rule has followed, LL-37 awaits committee review, and thymosin alpha-1 was reviewed in 2024 with FDA proposing not to list it. None may be compounded as of October 2026. Food proteins such as collagen and the amino acid glutamine are legal supplements, as long as they are not sold with disease claims.

+−Is there a natural alternative to prednisone for inflammation?

Not one that has been shown to do prednisone's job. No peptide, supplement or food has trial evidence of controlling a flare of ulcerative colitis, Crohn's disease or another condition that needs steroids. Do not stop prednisone on your own after more than a short course, because the body's own cortisol production is suppressed and stopping abruptly can be dangerous. The evidence-based route off steroids is a steroid-sparing drug chosen with your clinician, such as the immunomodulators and biologics in gastroenterology guidelines.

+−Is there a downside to taking peptides for gut health?

Several. None of the marketed gut peptides has human safety data from a controlled trial at the doses sold; the products are research chemicals with no verified content or sterility; a peptide that dampens immune signaling carries the same theoretical infection risk as the drugs that do so with monitoring; and the biggest risk is indirect, delaying or replacing treatment for a disease that can cause lasting damage when it is undertreated.

+−How long does it take for BPC-157 to work?

Nobody knows, because no human study of BPC-157 has measured a gut outcome over time. In rats, effects on fistulas and colitis were reported within days to four weeks of daily dosing that began within an hour of the injury. Timelines on seller sites are not based on any human data.

Sources

1. GuidelineRubin DT et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol 2025;120:1187-224. (2025)
2. GuidelineLacy BE et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021;116:17-44. (2021)
3. StudyJeppesen PB et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012;143:1473-81. (2012)
4. StudyLeffler DA et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 2015;148:1311-9. (2015)
5. SourceClinicalTrials.gov NCT03569007. Phase 3 study to evaluate the efficacy and safety of larazotide acetate for the relief of celiac disease symptoms: 307 enrolled, terminated by the sponsor, no results posted (record last updated July 2022). (2022)
6. LabelLODOCO (colchicine tablets 0.5 mg) prescribing information, DailyMed, version of August 2026 (indication to reduce cardiovascular events; LoDoCo2 trial results; contraindications). (2026)
7. StudyKlicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008;108:7-17. (2008)
8. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
9. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
10. StudyWu J et al. The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ 2025;388:e082583. (2025)
11. StudyMahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen 2021;29:938-50. (2021)
12. StudyKoon HW et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology 2011;141:1852-63. (2011)
13. StudyLande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9. (2007)
14. StudyZhou Q et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut 2019;68:996-1002. (2019)
15. StudyAbrahams M, O'Grady R, Prawitt J. Effect of a daily collagen peptide supplement on digestive symptoms in healthy women: 2-phase mixed methods study. JMIR Form Res 2022;6:e36339. (2022)